Indicate whether each of the following descriptions better applies to trastuzumab (T) which targets Her2, imatinib (I) which targets Bcr-Abl, or ipilimumab (P) which targets the CTLA4 protein. Your answer would be a three-letter string composed of letters T, I, and P only, e.g. TTP.
( ) It is NOT an antibody.
( ) It counters the immunosuppressive microenvironment of tumors.
( ) It does not bind to a cancer cell component.